Lessons from immuno-oncology: A new era for cancer nanomedicine?

Wen Jiang; Hengfeng Yuan; Charles K. Chan; Christina A. Von Roemeling; Zuoqin Yan; Irving L. Weissman; Betty Y.S. Kim

doi:10.1038/nrd.2017.34

Lessons from immuno-oncology: A new era for cancer nanomedicine?

Wen Jiang, Hengfeng Yuan, Charles K. Chan, Christina A. Von Roemeling, Zuoqin Yan, Irving L. Weissman, Betty Y.S. Kim

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.

Original language	English (US)
Pages (from-to)	369-370
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	16
Issue number	6
DOIs	https://doi.org/10.1038/nrd.2017.34
State	Published - Jun 1 2017
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd.2017.34

Cite this

@article{de65eb6ce3414b72b18600450746d5ef,

title = "Lessons from immuno-oncology: A new era for cancer nanomedicine?",

abstract = "Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.",

author = "Wen Jiang and Hengfeng Yuan and Chan, {Charles K.} and {Von Roemeling}, {Christina A.} and Zuoqin Yan and Weissman, {Irving L.} and Kim, {Betty Y.S.}",

year = "2017",

month = jun,

day = "1",

doi = "10.1038/nrd.2017.34",

language = "English (US)",

volume = "16",

pages = "369--370",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Lessons from immuno-oncology

T2 - A new era for cancer nanomedicine?

AU - Jiang, Wen

AU - Yuan, Hengfeng

AU - Chan, Charles K.

AU - Von Roemeling, Christina A.

AU - Yan, Zuoqin

AU - Weissman, Irving L.

AU - Kim, Betty Y.S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.

AB - Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.

UR - http://www.scopus.com/inward/record.url?scp=85015629143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015629143&partnerID=8YFLogxK

U2 - 10.1038/nrd.2017.34

DO - 10.1038/nrd.2017.34

M3 - Review article

C2 - 28303024

AN - SCOPUS:85015629143

SN - 1474-1776

VL - 16

SP - 369

EP - 370

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 6

ER -

Lessons from immuno-oncology: A new era for cancer nanomedicine?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this